Inflammatory Biomarkers Are Associated With a Decline in Functional Status at Discharge in Children With Acute Respiratory Failure: An Exploratory Analysis.
Pediatric Overall Performance Category
acute respiratory failure
functional outcomes
interleukin-1 receptor antagonist
thrombomodulin
Journal
Critical care explorations
ISSN: 2639-8028
Titre abrégé: Crit Care Explor
Pays: United States
ID NLM: 101746347
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
entrez:
19
7
2021
pubmed:
20
7
2021
medline:
20
7
2021
Statut:
epublish
Résumé
To evaluate the link between early acute respiratory failure and functional morbidity in survivors using the plasma biomarkers interleukin-8, interleukin-1 receptor antagonist, thrombomodulin, and plasminogen activator inhibitor-1. We hypothesized that children with acute respiratory failure with higher levels of inflammation would have worse functional outcomes at discharge, as measured by Pediatric Overall Performance Category. Secondary analysis of the Genetic Variation and Biomarkers in Children with Acute Lung Injury (R01HL095410) study. Twenty-two PICUs participating in the multisite clinical trial, Randomized Evaluation of Sedation Titration for Respiratory Failure (U01 HL086622) and the ancillary study (Biomarkers in Children with Acute Lung Injury). Children 2 weeks to 17 years requiring invasive mechanical ventilation for acute airways and/or parenchymal lung disease. Patients with an admission Pediatric Overall Performance Category greater than 3 (severe disability, coma, or brain death) were excluded. None. Among survivors, 387 patients had no worsening of Pediatric Overall Performance Category at discharge while 40 had worsening functional status, defined as any increase in Pediatric Overall Performance Category from baseline. There was no significant relationship between worsening of Pediatric Overall Performance Category and interleukin-8 or plasminogen activator inhibitor-1 on any day. There was no significant relationship between interleukin-1 receptor antagonist, or thrombomodulin, and worsening Pediatric Overall Performance Category on day 1. Plasma interleukin-1 receptor antagonist and thrombomodulin were significantly elevated on days 2 and 3 in those with worse functional status at discharge compared with those without. In multivariable analysis, interleukin-1 receptor antagonist and thrombomodulin were associated with a decline in functional status on days 2 and 3 after adjustment for age and highest oxygenation index. However, after adjusting for age and cardiovascular failure, only day 2 thrombomodulin levels were associated with a worsening in Pediatric Overall Performance Category. Higher levels of interleukin-1 receptor antagonist or thrombomodulin following intubation were associated with worse Pediatric Overall Performance Category scores at hospital discharge in children who survive acute respiratory failure. These data suggest that persistent inflammation may be related to functional decline.
Identifiants
pubmed: 34278308
doi: 10.1097/CCE.0000000000000467
pmc: PMC8280074
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e0467Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL095410
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL086622
Pays : United States
Informations de copyright
Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine.
Références
N Engl J Med. 2001 Aug 9;345(6):408-16
pubmed: 11496851
Pediatr Crit Care Med. 2019 Feb;20(2):120-127
pubmed: 30418338
Crit Care. 2019 Apr 17;23(1):128
pubmed: 30995942
Crit Care Med. 2016 Nov;44(11):2052-2059
pubmed: 27355525
Lancet Respir Med. 2018 Sep;6(9):691-698
pubmed: 30078618
Crit Care Res Pract. 2012;2012:614545
pubmed: 22482044
Immunol Rev. 2018 Jan;281(1):8-27
pubmed: 29247995
Intensive Care Med. 2010 Jan;36(1):157-63
pubmed: 19855955
Pediatr Crit Care Med. 2016 May;17(5):e247-59
pubmed: 27030932
N Engl J Med. 2011 Apr 7;364(14):1293-304
pubmed: 21470008
JAMA. 2015 Jan 27;313(4):379-89
pubmed: 25602358
Am J Respir Crit Care Med. 2019 Oct 1;200(7):900-909
pubmed: 31034245
Front Pediatr. 2016 Jun 01;4:55
pubmed: 27313995
Pediatr Crit Care Med. 2018 Oct;19(10):930-938
pubmed: 30095747
Crit Care Med. 2020 Aug;48(8):1120-1128
pubmed: 32697481
Pediatr Crit Care Med. 2021 Jan 1;22(1):40-49
pubmed: 33031352
Crit Care Med. 2020 Mar;48(3):319-328
pubmed: 32058369
J Pediatr. 1992 Jul;121(1):68-74
pubmed: 1625096
Chest. 2020 Sep;158(3):1027-1035
pubmed: 32275979
Crit Care. 2015 Dec 14;19:435
pubmed: 26652251
J Pharmacol Sci. 2020 May;143(1):17-22
pubmed: 32122774
Ann Transl Med. 2019 Oct;7(19):505
pubmed: 31728358
Intensive Care Med. 2016 May;42(5):725-738
pubmed: 27025938
Lancet Respir Med. 2019 Feb;7(2):115-128
pubmed: 30361119
Am J Respir Crit Care Med. 2018 Jun 1;197(11):1457-1467
pubmed: 29313710
Intensive Care Med. 2015 Mar;41(3):470-8
pubmed: 25643902
Crit Care Med. 2012 Apr;40(4):1309-16
pubmed: 22202709
JAMA Netw Open. 2019 Mar 1;2(3):e191179
pubmed: 30924897
Crit Care Med. 2018 Nov;46(11):1731-1738
pubmed: 30024428
Intensive Care Med. 2016 Jul;42(7):1137-45
pubmed: 27101828